Efficacy and safety of donafenib plus transarterial chemoembolization and immunotherapy for hepatocellular carcinoma

Table 1 Baseline clinicopathological parameters of enrolled patients

Parameters	No.
Age (years)
≤ 65	23
> 65	7
Gender
Male	29
Female	1
HBV infection
Yes	29
No	1
HCV infection
Yes	0
No	30
Child–Pugh score
A	28
B	2
AFP (ng/mL)
≤ 400	17
> 400	13
PIVKA (mAU/mL)
Median level	1423.50
ECOG-PS
0	29
1	1
BCLC stage
B	4
C	26

HBV: Hepatitis B virus; HCV: Hepatitis C virus; BCLC: Barcelona Clinic Liver Cancer; AFP: Alpha-fetoprotein; ECOG-PS: Eastern Cooperative Oncology Group Performance Status; PIVKA: Protein induced by vitamin K absence.